OCT 04, 2016 8:00 AM PDT

Overcoming the Clinical Sample Bottleneck for Expression Studies

Sponsored by: Affymetrix, Affymetrix
Speakers
  • Helene Roberson Professor of Pediatrics, Washington University School of Medicine
    BIOGRAPHY
  • Assistant Professor, Department of Medicine-Infectious Disease; Associate Director, Vaccine Testing Center, University of Vermont College of Medicine
    BIOGRAPHY

Abstract
DATE:  October 4, 2016
TIME:  8:00am PT, 11:00am ET

Extracting robust expression data from clinical samples represents a unique opportunity to find actionable biomarkers. But it does not come without challenges. Clinical samples such as whole blood and feces are technically challenging to work with, often of poor quality, and provide limited amounts of high-quality RNA making it difficult to generate reproducible and informative expression data.
 
Feces, in particular, are increasingly identified as useful non-invasive samples for molecular diagnosis of infectious disease, but their composition consists of a complex microbial community making the identification of human RNA signatures problematic. Whole blood is also a desirable sample type as it is widely available and collection is relatively non-invasive and inexpensive. Yet 70% of mRNA in whole blood is globin mRNA released from red blood cells, introducing noise and decreasing the sensitivity for detecting relevant transcripts. Most expression technologies require the removal of globin mRNA from the sample before processing, a time-consuming and costly step that introduces bias. Due to such challenges, researchers are demanding better expression methods for use with clinical samples, like whole blood and feces.
 
Choosing the right transcriptome profiling tool compatible with clinical samples is key to generating informative biomarkers that can be used to improve human health.
 
During this webinar, leading translational researchers will:
  • Demonstrate how novel transcriptome profiling assays can reliably identify biomarkers from even the most challenging of samples including feces.
  • Explain how to generate robust expression data from small amounts of whole blood without the need to eliminate globin mRNA, saving time and money while retaining data integrity.
  • Discuss the importance of choosing the right technology to obtain reliable data from rare samples while still preserving material for future use.  
  • Answer your questions live during the broadcast!

For Research Use Only. Not for use in diagnostic procedures. 

Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
NOV 17, 2021 8:00 AM PST
C.E. CREDITS
NOV 17, 2021 8:00 AM PST
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
OCT 27, 2021 6:00 AM PDT
C.E. CREDITS
OCT 27, 2021 6:00 AM PDT
Date: October 27, 2021 Time: 6:00 AM PDT, 9:00 AM EDT Etanercept is a recombinant Fc fusion protein therapeutic that has a complex distribution of post-translation modifications (PTM), such...
Loading Comments...
Show Resources